SlideShare a Scribd company logo
Prescription Drug Monitoring Program | State of California -
Department of Justice
Controlled Substance Utilization Review and Evaluation System (CURES) CURES 2.0 Soft Launch
and Phased Rollout
June 30, 2015
The Department of Justice (DOJ) and the Department of Consumer Affairs (DCA) are pleased to
announce that the states new Controlled Substance Utilization Review and Evaluation System
commonly referred to as CURES 2.0 will go live on July 1, 2015. This upgraded prescription drug
monitoring program features a variety of performance improvements and added functionality.
In order to ensure a smooth transition from the current system, CURES 2.0 will be rolled out to
users in phases over the next several months, beginning with early adoption by a select group of
users who currently use CURES and meet the CURES 2.0 security standards, including minimum
browser specifications.** DOJ is currently identifying prescribers and dispensers who meet these
criteria and will contact and coordinate their enrollment into CURES 2.0. For all other current users,
access to CURES 1.0 will not change and no action is needed at this time. For users and entities not
currently enrolled in CURES, further notification will be provided in August as to the
enrollment/registration process.
Practitioners and health systems should begin to prepare for universal adoption of the system by
January 2016, at which point all users will be required to meet CURES 2.0s security standards. If
you have any questions please contact cures@doj.ca.gov.
Thank you for your continued support of the CURES program.
**CURES 2.0 users will be required to use Microsoft Internet Explorer Version 11.0 or greater,
Mozilla FireFox, Google Chrome, or Safari when accessing the system.
CURES Contact Information: cures@doj.ca.gov or (916) 227-3843
The Controlled Substance Utilization Review and Evaluation System (CURES) is a database
containing information on Schedule II through IV controlled substances dispensed in California. It is
a valuable investigative, preventive, and educational tool for the healthcare community, regulatory
boards, and law enforcement.
The California Prescription Drug Monitoring Program (PDMP) maintains the CURES database. The
PDMP allows authorized users, including licensed healthcare prescribers eligible to prescribe
controlled substances, pharmacists authorized to dispense controlled substances, law enforcement,
and regulatory boards, to access patient controlled substance history information maintained in
CURES. The PDMP is committed to assisting in the reduction of pharmaceutical drug diversion
without affecting legitimate medical practice or patient care.
Through online access to CURES, authorized prescribers and pharmacists can quickly review
information via Patient Activity Reports (PAR) in an effort to identify and deter drug abuse and
diversion through accurate and rapid tracking of Schedule II through IV controlled substances. In
2014, over 3.5 million PAR requests were processed.
To obtain access to CURES, prescribers and pharmacists must: (1) submit an application form
electronically; and (2) mail a notarized copy of their printed and signed Application Confirmation,
along with copies of the following supporting documents: Drug Enforcement Administration
registration certificate (prescribers only), medical or pharmacist license, and a government-issued
photo identification. Applicants can email their complete CURES application packet to
pmp@doj.ca.gov or mail by standard U.S. mail to:
California Department of Justice
PDMP/CURES
P.O. Box 160447
Sacramento, CA 95816
The Department of Justice (DOJ) limits access to and dissemination of CURES information to
licensed prescribers, licensed pharmacists, law enforcement personnel, and regulatory board
personnel strictly for patient care or official investigatory/regulatory purposes. The DOJ pursues
regulatory and/or criminal sanctions for misuse of CURES information.
The Health Insurance Portability and Accountability Act of 1966 (HIPAA) and all confidentiality and
disclosure provisions of California law cover the information contained in CURES. All users must
comply with HIPAA Privacy Rule Requirements when using CURES.
Submission of Controlled Substance Data
California Health & Safety Code Section 11165(d) requires dispensing pharmacies, clinics, or other
dispensers of Schedule II through IV controlled substances to provide specified dispensing
information to the DOJ on a weekly basis in a format approved and accepted by the DOJ. Currently,
the ASAP 2009 Version 4.1 format is accepted.
Direct Dispense Reporting Application
The DOJ, in coordination with Atlantic Associates, Inc. (AAI), allows direct dispense prescribers and
entities, including pharmacies filling less than 25 prescriptions per month, to electronically report
dispensing data to the DOJ. The direct dispense application can be accessed on the Direct Dispense
website located at www.aaicures.com. Also available at this website are instructions on how to apply
for an account and submit dispense data. Please note that the DOJ no longer accepts paper direct
dispense reports.
To access the secured direct dispense site, dispensers must first complete the application at
http://aaicures.com/register.for.access.php. Once an application has been submitted, an email
confirmation from AAI will provide approved users with a username and temporary password. If an
email confirmation is not received within 48 hours of submitting the application, please contact AAI
at CACures@aainh.com or (800) 539-3370.
For additional information concerning controlled substance prescription data reporting, please
contact AAI at CACures@aainh.com or (800) 539-3370.
Prescription Forms (For Prescribers)Obtain Security Prescription Forms
California law requires prescribers of any Schedule II through V controlled substance to obtain and
use tamper-resistant prescription forms ordered only from state-approved security printers. To order
tamper-resistant prescription forms, please refer to the Approved List of Security Prescription
Printers for vendors authorized by the DOJ and their contact information.
Report Lost or Stolen Prescription Forms
Reports of lost or stolen prescription forms or pads must be reported to local law enforcement and
the PDMP. Users registered with CURES can href="https://pmp.doj.ca.gov/pdmp/index.do"
target="_blank">electronically report their lost or stolen prescription forms or pads online when
logged into their CURES account. A law enforcement agency report number is required when
submitting a report of lost or stolen prescription forms to the PDMP.
For questions concerning how to report lost or stolen prescription pads or forms, please contact the
Security Prescription Printer Program at SecurityPrinter@doj.ca.gov.

More Related Content

What's hot

PCAT-1290 Provider_Manual
PCAT-1290 Provider_ManualPCAT-1290 Provider_Manual
PCAT-1290 Provider_Manual
Marian Maskow
 
Client Form - HIPPA form
Client Form - HIPPA formClient Form - HIPPA form
Client Form - HIPPA form
Market JD, Inc.
 
Hipaa fillable
Hipaa fillableHipaa fillable
Hipaa fillable
jjohnsebastianattorney
 
OLU_-_March2016_NE
OLU_-_March2016_NEOLU_-_March2016_NE
OLU_-_March2016_NE
Zoe Stetson
 
law of uaeon medical products
law of uaeon medical productslaw of uaeon medical products
law of uaeon medical products
Muhammed hamed albuissa
 
Compliance Today article March 2015
Compliance Today article March 2015Compliance Today article March 2015
Compliance Today article March 2015
Cristine Vogel
 
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Sathish Vemula
 
Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015
Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015
Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015
Sathish Vemula
 
Pharma Uptoday - Volume 3 issue jun 2014
Pharma Uptoday - Volume 3 issue jun 2014Pharma Uptoday - Volume 3 issue jun 2014
Pharma Uptoday - Volume 3 issue jun 2014
Sathish Vemula
 
6674912863_certificate
6674912863_certificate6674912863_certificate
6674912863_certificate
VUKSAN BULATOVIC MD
 
K153329.Letter.SE.FINAL_Sent001
K153329.Letter.SE.FINAL_Sent001K153329.Letter.SE.FINAL_Sent001
K153329.Letter.SE.FINAL_Sent001
Brian Kim
 
iHT² Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea...
 iHT²  Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea... iHT²  Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea...
iHT² Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea...
Health IT Conference – iHT2
 
My Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device RegulationsMy Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device Regulations
Harshit Thakkar
 
Online Application
Online ApplicationOnline Application
Online Application
Foodanddrug Regionone
 
FM 553211
FM 553211FM 553211
FM 553211
HD Surgical
 
Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015
Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015
Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015
Sathish Vemula
 
The 340B Program and Implications of the Mega Guidance
The 340B Program and Implications of the Mega GuidanceThe 340B Program and Implications of the Mega Guidance
The 340B Program and Implications of the Mega Guidance
CompleteRx
 
Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014
Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014
Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014
Sathish Vemula
 

What's hot (18)

PCAT-1290 Provider_Manual
PCAT-1290 Provider_ManualPCAT-1290 Provider_Manual
PCAT-1290 Provider_Manual
 
Client Form - HIPPA form
Client Form - HIPPA formClient Form - HIPPA form
Client Form - HIPPA form
 
Hipaa fillable
Hipaa fillableHipaa fillable
Hipaa fillable
 
OLU_-_March2016_NE
OLU_-_March2016_NEOLU_-_March2016_NE
OLU_-_March2016_NE
 
law of uaeon medical products
law of uaeon medical productslaw of uaeon medical products
law of uaeon medical products
 
Compliance Today article March 2015
Compliance Today article March 2015Compliance Today article March 2015
Compliance Today article March 2015
 
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
 
Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015
Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015
Pharma Uptoday Monthly Magazine - Volume 20; Issue: Nov 2015
 
Pharma Uptoday - Volume 3 issue jun 2014
Pharma Uptoday - Volume 3 issue jun 2014Pharma Uptoday - Volume 3 issue jun 2014
Pharma Uptoday - Volume 3 issue jun 2014
 
6674912863_certificate
6674912863_certificate6674912863_certificate
6674912863_certificate
 
K153329.Letter.SE.FINAL_Sent001
K153329.Letter.SE.FINAL_Sent001K153329.Letter.SE.FINAL_Sent001
K153329.Letter.SE.FINAL_Sent001
 
iHT² Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea...
 iHT²  Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea... iHT²  Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea...
iHT² Health IT Summit Denver - Laura McCrary,Executive Director, Kansas Hea...
 
My Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device RegulationsMy Presentation on Mexico Medical Device Regulations
My Presentation on Mexico Medical Device Regulations
 
Online Application
Online ApplicationOnline Application
Online Application
 
FM 553211
FM 553211FM 553211
FM 553211
 
Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015
Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015
Pharma Uptoday - Monthly magazine; Volume 17, Issue Aug 2015
 
The 340B Program and Implications of the Mega Guidance
The 340B Program and Implications of the Mega GuidanceThe 340B Program and Implications of the Mega Guidance
The 340B Program and Implications of the Mega Guidance
 
Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014
Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014
Pharma Uptoday Monthly Magazine Volume 8 issue Nov 2014
 

Similar to Prescription Drug Monitoring Program | State of California - Department of Justice

Part ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docx
Part ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docxPart ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docx
Part ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docx
danhaley45372
 
Medical Consumer Product Protection Legislation
Medical Consumer Product Protection LegislationMedical Consumer Product Protection Legislation
Medical Consumer Product Protection Legislation
Joseph Curtis
 
IPR NDA and ANDA
IPR NDA and ANDAIPR NDA and ANDA
IPR NDA and ANDA
mahender Kotte
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
Suhas Reddy C
 
free mHealth Checklist
free mHealth Checklistfree mHealth Checklist
free mHealth Checklist
Demet G. Sag
 
Planning Clinical Trial in USA.pdf
Planning Clinical Trial in USA.pdfPlanning Clinical Trial in USA.pdf
Planning Clinical Trial in USA.pdf
ProRelix Research
 
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
NextWorks
 
Data Exclusivity
Data ExclusivityData Exclusivity
Data Exclusivity
DSPIntellects
 
Scary acronyms
Scary acronymsScary acronyms
Scary acronyms
Deven McGraw
 
Health Insurance Portability & Accountability Act (HIPAA)
Health Insurance Portability & Accountability Act (HIPAA)Health Insurance Portability & Accountability Act (HIPAA)
Health Insurance Portability & Accountability Act (HIPAA)
Arpitha Aarushi
 
FDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & SafetyFDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & Safety
Dr Dev Kambhampati
 
Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011
Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011
Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011
Matt Sherer
 
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docxTHE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
oreo10
 
http1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docx
http1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docxhttp1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docx
http1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docx
pooleavelina
 
In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...
In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...
In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...
Patton Boggs LLP
 
Controlled Substances Laws (expired)
Controlled Substances Laws (expired)Controlled Substances Laws (expired)
Controlled Substances Laws (expired)
Lindon & Lindon, LLC
 
Hipaa 42 cfr review
Hipaa 42 cfr reviewHipaa 42 cfr review
Hipaa 42 cfr review
robint2125
 
regulatory aspects of medical devices in USA
regulatory aspects of medical devices in USAregulatory aspects of medical devices in USA
regulatory aspects of medical devices in USA
navyasribandaru
 
Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014 Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014
Sathish Vemula
 
5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)
Teleosis Institute
 

Similar to Prescription Drug Monitoring Program | State of California - Department of Justice (20)

Part ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docx
Part ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docxPart ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docx
Part ONE-1 page AMA format-due 917 by 1000 pm EST Evaluate m.docx
 
Medical Consumer Product Protection Legislation
Medical Consumer Product Protection LegislationMedical Consumer Product Protection Legislation
Medical Consumer Product Protection Legislation
 
IPR NDA and ANDA
IPR NDA and ANDAIPR NDA and ANDA
IPR NDA and ANDA
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
free mHealth Checklist
free mHealth Checklistfree mHealth Checklist
free mHealth Checklist
 
Planning Clinical Trial in USA.pdf
Planning Clinical Trial in USA.pdfPlanning Clinical Trial in USA.pdf
Planning Clinical Trial in USA.pdf
 
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
HIGHLIGHTED: Dissemination of Patient-Specific Information from Devices by De...
 
Data Exclusivity
Data ExclusivityData Exclusivity
Data Exclusivity
 
Scary acronyms
Scary acronymsScary acronyms
Scary acronyms
 
Health Insurance Portability & Accountability Act (HIPAA)
Health Insurance Portability & Accountability Act (HIPAA)Health Insurance Portability & Accountability Act (HIPAA)
Health Insurance Portability & Accountability Act (HIPAA)
 
FDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & SafetyFDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & Safety
 
Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011
Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011
Guidi Sherer Everything You Wanted to Know About 340B Oncology Issues 2011
 
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docxTHE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
THE MEDICINE SHOPPE V. LORETTA LYNCH, ETAL. PHARMACISTS A.docx
 
http1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docx
http1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docxhttp1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docx
http1500cms.comBECAUSE THIS FORM IS USED BY VARIOUS .docx
 
In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...
In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...
In Good News For Providers, OIG and CMS Propose Extensions And Modifications ...
 
Controlled Substances Laws (expired)
Controlled Substances Laws (expired)Controlled Substances Laws (expired)
Controlled Substances Laws (expired)
 
Hipaa 42 cfr review
Hipaa 42 cfr reviewHipaa 42 cfr review
Hipaa 42 cfr review
 
regulatory aspects of medical devices in USA
regulatory aspects of medical devices in USAregulatory aspects of medical devices in USA
regulatory aspects of medical devices in USA
 
Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014 Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014
 
5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)5.4. Federal Regulations (Batz)
5.4. Federal Regulations (Batz)
 

Prescription Drug Monitoring Program | State of California - Department of Justice

  • 1. Prescription Drug Monitoring Program | State of California - Department of Justice Controlled Substance Utilization Review and Evaluation System (CURES) CURES 2.0 Soft Launch and Phased Rollout June 30, 2015 The Department of Justice (DOJ) and the Department of Consumer Affairs (DCA) are pleased to announce that the states new Controlled Substance Utilization Review and Evaluation System commonly referred to as CURES 2.0 will go live on July 1, 2015. This upgraded prescription drug monitoring program features a variety of performance improvements and added functionality. In order to ensure a smooth transition from the current system, CURES 2.0 will be rolled out to users in phases over the next several months, beginning with early adoption by a select group of users who currently use CURES and meet the CURES 2.0 security standards, including minimum browser specifications.** DOJ is currently identifying prescribers and dispensers who meet these criteria and will contact and coordinate their enrollment into CURES 2.0. For all other current users, access to CURES 1.0 will not change and no action is needed at this time. For users and entities not currently enrolled in CURES, further notification will be provided in August as to the enrollment/registration process. Practitioners and health systems should begin to prepare for universal adoption of the system by January 2016, at which point all users will be required to meet CURES 2.0s security standards. If you have any questions please contact cures@doj.ca.gov. Thank you for your continued support of the CURES program. **CURES 2.0 users will be required to use Microsoft Internet Explorer Version 11.0 or greater, Mozilla FireFox, Google Chrome, or Safari when accessing the system. CURES Contact Information: cures@doj.ca.gov or (916) 227-3843 The Controlled Substance Utilization Review and Evaluation System (CURES) is a database containing information on Schedule II through IV controlled substances dispensed in California. It is a valuable investigative, preventive, and educational tool for the healthcare community, regulatory boards, and law enforcement. The California Prescription Drug Monitoring Program (PDMP) maintains the CURES database. The PDMP allows authorized users, including licensed healthcare prescribers eligible to prescribe controlled substances, pharmacists authorized to dispense controlled substances, law enforcement, and regulatory boards, to access patient controlled substance history information maintained in CURES. The PDMP is committed to assisting in the reduction of pharmaceutical drug diversion without affecting legitimate medical practice or patient care. Through online access to CURES, authorized prescribers and pharmacists can quickly review information via Patient Activity Reports (PAR) in an effort to identify and deter drug abuse and
  • 2. diversion through accurate and rapid tracking of Schedule II through IV controlled substances. In 2014, over 3.5 million PAR requests were processed. To obtain access to CURES, prescribers and pharmacists must: (1) submit an application form electronically; and (2) mail a notarized copy of their printed and signed Application Confirmation, along with copies of the following supporting documents: Drug Enforcement Administration registration certificate (prescribers only), medical or pharmacist license, and a government-issued photo identification. Applicants can email their complete CURES application packet to pmp@doj.ca.gov or mail by standard U.S. mail to: California Department of Justice PDMP/CURES P.O. Box 160447 Sacramento, CA 95816 The Department of Justice (DOJ) limits access to and dissemination of CURES information to licensed prescribers, licensed pharmacists, law enforcement personnel, and regulatory board personnel strictly for patient care or official investigatory/regulatory purposes. The DOJ pursues regulatory and/or criminal sanctions for misuse of CURES information. The Health Insurance Portability and Accountability Act of 1966 (HIPAA) and all confidentiality and disclosure provisions of California law cover the information contained in CURES. All users must comply with HIPAA Privacy Rule Requirements when using CURES. Submission of Controlled Substance Data California Health & Safety Code Section 11165(d) requires dispensing pharmacies, clinics, or other dispensers of Schedule II through IV controlled substances to provide specified dispensing information to the DOJ on a weekly basis in a format approved and accepted by the DOJ. Currently, the ASAP 2009 Version 4.1 format is accepted.
  • 3. Direct Dispense Reporting Application The DOJ, in coordination with Atlantic Associates, Inc. (AAI), allows direct dispense prescribers and entities, including pharmacies filling less than 25 prescriptions per month, to electronically report dispensing data to the DOJ. The direct dispense application can be accessed on the Direct Dispense website located at www.aaicures.com. Also available at this website are instructions on how to apply for an account and submit dispense data. Please note that the DOJ no longer accepts paper direct dispense reports. To access the secured direct dispense site, dispensers must first complete the application at http://aaicures.com/register.for.access.php. Once an application has been submitted, an email confirmation from AAI will provide approved users with a username and temporary password. If an email confirmation is not received within 48 hours of submitting the application, please contact AAI at CACures@aainh.com or (800) 539-3370. For additional information concerning controlled substance prescription data reporting, please contact AAI at CACures@aainh.com or (800) 539-3370. Prescription Forms (For Prescribers)Obtain Security Prescription Forms California law requires prescribers of any Schedule II through V controlled substance to obtain and use tamper-resistant prescription forms ordered only from state-approved security printers. To order tamper-resistant prescription forms, please refer to the Approved List of Security Prescription Printers for vendors authorized by the DOJ and their contact information. Report Lost or Stolen Prescription Forms Reports of lost or stolen prescription forms or pads must be reported to local law enforcement and the PDMP. Users registered with CURES can href="https://pmp.doj.ca.gov/pdmp/index.do" target="_blank">electronically report their lost or stolen prescription forms or pads online when
  • 4. logged into their CURES account. A law enforcement agency report number is required when submitting a report of lost or stolen prescription forms to the PDMP. For questions concerning how to report lost or stolen prescription pads or forms, please contact the Security Prescription Printer Program at SecurityPrinter@doj.ca.gov.